Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $16.0 million.

  • Mirum Pharmaceuticals' Other Non-Current Liabilities rose 30234.14% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 30234.14%. This contributed to the annual value of $2.5 million for FY2024, which is 3481.42% down from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Other Non-Current Liabilities stood at $16.0 million, which was up 30234.14% from $9.1 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Other Non-Current Liabilities registered a high of $141.7 million during Q1 2023, and its lowest value of $7000.0 during Q3 2023.
  • Its 5-year average for Other Non-Current Liabilities is $61.8 million, with a median of $16.0 million in 2025.
  • In the last 5 years, Mirum Pharmaceuticals' Other Non-Current Liabilities skyrocketed by 42082333.33% in 2021 and then tumbled by 9999.49% in 2023.
  • Mirum Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $129.9 million in 2021, then rose by 8.03% to $140.4 million in 2022, then tumbled by 97.26% to $3.8 million in 2023, then crashed by 34.81% to $2.5 million in 2024, then skyrocketed by 536.95% to $16.0 million in 2025.
  • Its Other Non-Current Liabilities stands at $16.0 million for Q3 2025, versus $9.1 million for Q2 2025 and $13.9 million for Q1 2025.